{
    "organizations": [],
    "uuid": "ee6477bbfe9098aa3b098b01bb7a1becab3856c9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-immune-pharmaceuticals-says-board/brief-immune-pharmaceuticals-says-board-will-not-pursue-spin-off-of-cytovia-unit-idUSASC0A02Y",
    "ord_in_thread": 0,
    "title": "Immune Pharmaceuticals Says Board Will Not Pursue Spin-Off Of Cytovia Unit",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 7 (Reuters) - Immune Pharmaceuticals Inc:\n* IMMUNE PHARMACEUTICALS PROVIDES UPDATE ON PLANS FOR ONCOLOGY SUBSIDIARY, CYTOVIA, INC.\n* IMMUNE PHARMACEUTICALS INC - COMPANY’S BOARD WILL NO LONGER PURSUE A SPIN-OFF OF ITS ONCOLOGY-FOCUSED SUBSIDIARY, CYTOVIA INC\n* IMMUNE PHARMACEUTICALS - DANIEL TEPER HAS RESIGNED AS CEO OF CYTOVIA AND FROM BOARD OF DIRECTORS OF BOTH CYTOVIA AND IMMUNE, EFFECTIVE IMMEDIATELY\n* IMMUNE PHARMACEUTICALS INC - CYTOVIA INC HAD BEEN LED BY IMMUNE’S FOUNDER AND FORMER CHIEF EXECUTIVE OFFICER DANIEL TEPER\n* IMMUNE PHARMACEUTICALS INC - HAS INITIATED DISCUSSIONS WITH PARTIES POTENTIALLY INTERESTED IN ACQUIRING CERTAIN OF CYTOVIA’S ASSETS\n* IMMUNE PHARMACEUTICALS INC - IMMUNE WILL CONTINUE TO FOCUS ITS EFFORTS AND RESOURCES ON DEVELOPMENT OF ITS CORE PROGRAMS, BERTILIMUMAB AND NANOCYCLO Source text for Eikon:\nOur ",
    "published": "2018-05-07T20:40:00.000+03:00",
    "crawled": "2018-05-08T16:38:16.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "immune",
        "pharmaceutical",
        "inc",
        "immune",
        "pharmaceutical",
        "provides",
        "update",
        "plan",
        "oncology",
        "subsidiary",
        "cytovia",
        "immune",
        "pharmaceutical",
        "inc",
        "company",
        "board",
        "longer",
        "pursue",
        "subsidiary",
        "cytovia",
        "inc",
        "immune",
        "pharmaceutical",
        "daniel",
        "teper",
        "resigned",
        "ceo",
        "cytovia",
        "board",
        "director",
        "cytovia",
        "immune",
        "effective",
        "immediately",
        "immune",
        "pharmaceutical",
        "inc",
        "cytovia",
        "inc",
        "led",
        "immune",
        "founder",
        "former",
        "chief",
        "executive",
        "officer",
        "daniel",
        "teper",
        "immune",
        "pharmaceutical",
        "inc",
        "initiated",
        "discussion",
        "party",
        "potentially",
        "interested",
        "acquiring",
        "certain",
        "cytovia",
        "asset",
        "immune",
        "pharmaceutical",
        "inc",
        "immune",
        "continue",
        "focus",
        "effort",
        "resource",
        "development",
        "core",
        "program",
        "bertilimumab",
        "nanocyclo",
        "source",
        "text",
        "eikon"
    ]
}